BiotechTube
Red Glead Discovery

Red Glead Discovery

Lund, Sweden· Est.
rgdiscovery.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

RG Discovery is a private, revenue-generating Scandinavian CRO founded in 2016, offering end-to-end drug discovery services with a focus on small molecules and peptide macrocycles. The company leverages its integrated platform of medicinal chemistry, computational science, analytical services (including NMR and SFC), and in vitro biology to execute fast design-make-test cycles for clients. Positioned in the Medicon Valley life science cluster, it serves global pharmaceutical and biotech companies, emphasizing close collaboration and sustainable practices to advance client projects from hit-finding to clinical candidates.

Oncology

Technology Platform

Integrated drug discovery service platform specializing in small molecules, peptides, and macrocycles. Combines medicinal and synthetic chemistry, computational design, analytical services (HPLC, UPLC, MS, NMR, SFC), in vitro biology/ADME profiling, and compound management to execute rapid design-make-test cycles for clients.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

Growing industry demand for outsourcing integrated drug discovery, particularly for complex modalities like macrocyclic peptides.
Strategic location in the Medicon Valley cluster provides access to a dense network of biotech and pharma clients.
Increasing focus on sustainable chemistry practices presents a potential differentiation point.

Risk Factors

Revenue dependency on a competitive project-based CRO model subject to client concentration and industry R&D cycles.
Intense competition from large global and niche CROs requires constant demonstration of superior scientific value.
Critical reliance on recruiting and retaining top scientific talent in a competitive regional market.

Competitive Landscape

Competes in the fragmented drug discovery CRO market against large global players (e.g., Charles River, Evotec, WuXi AppTec) and numerous specialized European CROs. Differentiation is based on deep expertise in peptide/macrocycle chemistry, integrated 'one-site' service model, and high-touch collaboration. Niche focus on complex chemistry and NMR-driven conformational analysis is a key competitive edge.

More companies in Small Molecule Drugs →More companies in Sweden →